Delving into the Latest Updates on Naftifine Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Naftifine, Naftifine HCl, Naftifine Hydrochloride Cream

+ [13]

Target

SQLE

Mechanism

SQLE inhibitors(Squalene monooxygenase inhibitors)

Therapeutic Areas

Infectious DiseasesSkin and Musculoskeletal Diseases

Active Indication

Tinea corporistinea crurisTinea Pedis

Inactive Indication

Tinea Capitis

Originator Organization

Merz Pharma GmbH & Co. KGaA

Active Organization

Sebela Ireland Ltd.

Inactive Organization

GenZum Life Sciences LLC

Merz North America, Inc.Taro Pharmaceuticals U.S.A., Inc.

Drug Highest PhaseApproved

First Approval Date

US (29 Feb 1988),

Tinea corporistinea crurisTinea Pedis

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC21H21N

InChIKeyOZGNYLLQHRPOBR-DHZHZOJOSA-N

CAS Registry65472-88-0

View All Structures (2)

The widespread use of sub-therapeutic antibiotics may lead to treatment failures, increased resistance to antibiotics, and even the encouragement of the formation of superbugs. Fraudulent herbal medicines that actually contain unlabeled active ingredients are a global problem. Therefore, streamlined and accurate analytical techniques that can identify and quantify a variety of antimicrobials in suspected illegal products are required. In the present work, we developed a sensitive, robust, and accurate method that involves multi-step extraction, EMR-lipid-based pass-through cleanup, and UHPLC-Q/HRMS with an orbital ion trap instrument analysis for the simultaneous detection of ten illicit antifungal drugs (flucytosine, fluconazole, ketoconazole, naftifine hydrochloride, griseofulvin, bifonazole, econazole nitrate, elubiol, clotrimazole, and miconazole nitrate) in herbal disinfection products. This validated method was then applied to 210 authentic samples, resulting in 25% of the samples being positive for the drugs. The results suggested the need to strengthen controls in this field to detect illicit antifungal drugs in herbal bacteriostatic products, which represents a potential health risk for the consumer. On a global scale, more and more frequent routine monitoring is being carried out in this area. This study provides valuable insights into large-scale complex sample chemical profiling, and the method developed appears to be promising and applicable for high-throughput routine multiple antibiotic analysis in a complex sample matrix.

01 Aug 2024·Mycopathologia

A Giant Panda’s Skin and Hairs Infection of Nannizzia Gypsum on Lumbosacral Region Successfully Treated by Oral Terbinafine and Topic Naftifine-ketoconazole Cream

Article

Author: Xu, Xiaoxi ; Huang, Junwen ; Ran, Yuping ; Luo, Li

In this study, An 8-mo-old female giant panda from the Chengdu Research Base of Giant Panda Breeding developed a hair loss area of 15 9 20 cm on the lumbosacral.Region for 4 days, accompanied with skin ulceration and pus discharging.It needed breastfeeding every night, but its mother and brother didn't reveal similar skin lesions.While the panda was under general anesthesia, veterinarians performed debridement, and collected secretion and hair samples from the lesions.The DNA was amplified by ITS1/4 primer-based PCR (ITS1:50-TCCGTAGGTGAACCTGCGG-30, ITS4: 50-TC CTCCGCTTATTGATATGC-30), the products were sequenced and BLASTed, and identified as Nannizzia gypsum (Accession Numbers: MN314834 and MN315461).Oral antifungal drug is not only convenient but also prevents pathogens from spreading from lesion site to other parts of the body.

01 Jul 2024·Nature Nanotechnology

Multimodal nanoimmunotherapy engages neutrophils to eliminate Staphylococcus aureus infections

Article

Author: Gao, Ruixuan ; Xie, Ruosen ; Tong, Yao ; Gong, Shaoqin ; Ye, Mingzhou ; Burger, Jacobus C ; Zhu, Min ; Zhao, Yi ; Yodsanit, Nisakorn ; Zhu, Jingcheng

The increasing prevalence of antimicrobial resistance in Staphylococcus aureus necessitates alternative therapeutic approaches. Neutrophils play a crucial role in the fight against S. aureus but suffer from deficiencies in function leading to increased infection. Here we report a nanoparticle-mediated immunotherapy aimed at potentiating neutrophils to eliminate S. aureus. The nanoparticles consist of naftifine, haemoglobin (Hb) and a red blood cell membrane coating. Naftifine disrupts staphyloxanthin biosynthesis, Hb reduces bacterial hydrogen sulfide levels and the red blood cell membrane modifies bacterial lipid composition. Collectively, the nanoparticles can sensitize S. aureus to host oxidant killing. Furthermore, in the infectious microenvironment, Hb triggers lipid peroxidation in S. aureus, promoting neutrophil chemotaxis. Oxygen supplied by Hb can also significantly enhance the bactericidal capability of the recruited neutrophils by restoring neutrophil respiratory burst via hypoxia relief. This multimodal nanoimmunotherapy demonstrates excellent therapeutic efficacy in treating antimicrobial-resistant S. aureus persisters, biofilms and S. aureus-induced infection in mice.

100 Deals associated with Naftifine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00883	Naftifine Hydrochloride	D01AE22	DB00735

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Tinea corporis	US	Sebela Ireland Ltd.	29 Feb 1988
tinea cruris	US	Sebela Ireland Ltd.	29 Feb 1988
Tinea Pedis	US	Sebela Ireland Ltd.	29 Feb 1988

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
tinea cruris	Phase 1	PR	Merz North America, Inc.	01 Sep 2008
tinea cruris	Phase 1	US	Merz North America, Inc.	01 Sep 2008
Tinea Pedis	Phase 1	US	Merz North America, Inc.	01 Aug 2008

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01289015 (NAFT-600, CTgov)	Phase 3	Tinea Pedis	855	Placebo	kjfdfutqlj(haqnzmjidg) = tydljuzchj qxxrpemzsv (nwinwbkenl, crtvdlpthe - zdjynvtwpa) View more	-	26 Sep 2013
NCT00750139 (CTgov)	Phase 3	Tinea Pedis	707	Naftin (NAFT-500)	zpanvnoexn(ekwklftuhw) = vwnjroicvw icimwmjwmm (bsufmtztbz, gfbriizqvi - luwveklrxx) View more	-	29 Jan 2013
				Placebo (Placebo 2-weeks)	zpanvnoexn(ekwklftuhw) = yblnmknvmu icimwmjwmm (bsufmtztbz, ziavoqbexo - gndcwzmiub)
NCT00750152 (CTgov)	Phase 3	tinea cruris	334	Naftin (NAFT-500)	ukwtlqsaei(gqjbrqacve) = gmnqfqdytc ykowuzlqdq (jsvgugrmfx, pzaztodduu - mafvfxcwjq) View more	-	13 Mar 2012
				Placebo (Placebo-2wks)	ukwtlqsaei(gqjbrqacve) = oseupeeegp ykowuzlqdq (jsvgugrmfx, ondczclird - qxgcvjgejf) View more
NCT00750152 (Pubmed)	Phase 3	tinea cruris	334	Naftifine HCl 2% cream	blykvvtsuv(wxirxbrjls) = 1 per group dzgaygpbdb (jecrgpoecn ) View more	-	01 Oct 2011
				Vehicle